PL2396340T3 - Analogi karba-nukleozydu do terapii przeciwwirusowych - Google Patents

Analogi karba-nukleozydu do terapii przeciwwirusowych

Info

Publication number
PL2396340T3
PL2396340T3 PL10704068T PL10704068T PL2396340T3 PL 2396340 T3 PL2396340 T3 PL 2396340T3 PL 10704068 T PL10704068 T PL 10704068T PL 10704068 T PL10704068 T PL 10704068T PL 2396340 T3 PL2396340 T3 PL 2396340T3
Authority
PL
Poland
Prior art keywords
carba
nucleoside analogs
antiviral treatment
antiviral
treatment
Prior art date
Application number
PL10704068T
Other languages
English (en)
Inventor
Thomas Butler
Aesop Cho
Choung U Kim
Jie Xu
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42333309&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2396340(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PL2396340T3 publication Critical patent/PL2396340T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
PL10704068T 2009-02-10 2010-02-09 Analogi karba-nukleozydu do terapii przeciwwirusowych PL2396340T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15124809P 2009-02-10 2009-02-10
PCT/US2010/023586 WO2010093608A1 (en) 2009-02-10 2010-02-09 Carba-nucleoside analogs for antiviral treatment
EP10704068.5A EP2396340B1 (en) 2009-02-10 2010-02-09 Carba-nucleoside analogs for antiviral treatment

Publications (1)

Publication Number Publication Date
PL2396340T3 true PL2396340T3 (pl) 2014-05-30

Family

ID=42333309

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10704068T PL2396340T3 (pl) 2009-02-10 2010-02-09 Analogi karba-nukleozydu do terapii przeciwwirusowych

Country Status (27)

Country Link
US (1) US8012942B2 (pl)
EP (2) EP2396340B1 (pl)
JP (2) JP5746638B2 (pl)
KR (2) KR101834707B1 (pl)
CN (1) CN102348713B (pl)
AP (1) AP2922A (pl)
AU (3) AU2010213873B2 (pl)
BR (1) BRPI1013643A2 (pl)
CA (1) CA2751277C (pl)
CL (1) CL2011001906A1 (pl)
CO (1) CO6420354A2 (pl)
DK (1) DK2396340T3 (pl)
EA (1) EA025085B1 (pl)
ES (2) ES2453078T3 (pl)
HK (1) HK1163108A1 (pl)
HR (1) HRP20140219T1 (pl)
IL (1) IL214396A (pl)
MX (2) MX345562B (pl)
NZ (1) NZ594370A (pl)
PE (3) PE20160858A1 (pl)
PL (1) PL2396340T3 (pl)
PT (2) PT2396340E (pl)
SG (1) SG173186A1 (pl)
SI (1) SI2396340T1 (pl)
SM (1) SMT201400056B (pl)
UA (2) UA112140C2 (pl)
WO (1) WO2010093608A1 (pl)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CN1849142A (zh) 2002-11-15 2006-10-18 埃迪尼克斯(开曼)有限公司 2′－支链核苷和黄病毒突变
BRPI0911410A2 (pt) 2008-04-23 2015-10-06 Gilead Sciences Inc análogos de carba-nucleosídeo para tratamento antiviral
SI2480559T1 (sl) * 2009-09-21 2013-10-30 Gilead Sciences, Inc. Postopki in intermediati za pripravo 1'-ciano-karbanukleozidnih analogov
KR20200052384A (ko) 2010-07-19 2020-05-14 길리애드 사이언시즈, 인코포레이티드 부분입체 이성질성으로 순수한 포스포라미데이트 전구약물의 제조 방법
PT2595980E (pt) 2010-07-22 2014-11-27 Gilead Sciences Inc Métodos e compostos para tratar infeções pelo vírus da família paramyxoviridae
BR112013008017A2 (pt) * 2010-09-20 2016-06-14 Gilead Sciences Inc análogos de carba-nucleosídeo 2-flúor substituídos para tratamento antiviral
ES2716158T3 (es) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleótidos para el tratamiento de hepatitis C
WO2012154321A1 (en) 2011-03-31 2012-11-15 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
EP2768838A1 (en) 2011-10-14 2014-08-27 IDENIX Pharmaceuticals, Inc. Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
WO2013084165A1 (en) * 2011-12-05 2013-06-13 Medivir Ab Hcv polymerase inhibitors
US9073943B2 (en) 2012-02-10 2015-07-07 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
NZ702744A (en) 2012-05-22 2016-12-23 Idenix Pharmaceuticals Llc D-amino acid compounds for liver disease
WO2013177195A1 (en) 2012-05-22 2013-11-28 Idenix Pharmaceuticals, Inc. 3',5'-cyclic phosphate prodrugs for hcv infection
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
UY34824A (es) 2012-05-25 2013-11-29 Janssen R & D Ireland Nucleósidos de espirooxetano de uracilo
US9192621B2 (en) 2012-09-27 2015-11-24 Idenix Pharmaceuticals Llc Esters and malonates of SATE prodrugs
EA030189B8 (ru) 2012-10-08 2018-10-31 Иденикс Фармасьютикалз Ллс Аналоги 2'-хлоронуклеозидов для инфекции вгс
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
US9339541B2 (en) 2013-03-04 2016-05-17 Merck Sharp & Dohme Corp. Thiophosphate nucleosides for the treatment of HCV
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
EP2970357A1 (en) 2013-03-13 2016-01-20 IDENIX Pharmaceuticals, Inc. Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
CN105814068B (zh) * 2014-02-27 2017-08-04 四川海思科制药有限公司 一种取代的氨基磷酸酯类衍生物、其制备方法及其应用
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
TWI698444B (zh) 2014-10-29 2020-07-11 美商基利科學股份有限公司 製備核糖苷的方法
DK3236972T3 (en) 2014-12-26 2021-10-04 Univ Emory Antivirale N4-hydroxycytidin-derivativer
RU2764767C2 (ru) 2015-03-06 2022-01-21 Атеа Фармасьютикалс, Инк. β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-С-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ
US10011629B2 (en) * 2015-05-01 2018-07-03 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
CA2998189C (en) 2015-09-16 2021-08-03 Gilead Sciences, Inc. Methods for treating arenaviridae and coronaviridae virus infections
CN106083962B (zh) * 2016-06-08 2018-12-18 成都倍特药业有限公司 一种具有环磷酰胺结构的化合物及其制备方法
US10711029B2 (en) 2016-07-14 2020-07-14 Atea Pharmaceuticals, Inc. Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
PL3512863T3 (pl) 2016-09-07 2022-04-04 Atea Pharmaceuticals, Inc. 2'-Podstawione-N6-podstawione nukleotydy purynowe do leczenia zakażeń wirusem RNA
SG10202012214WA (en) 2017-02-01 2021-01-28 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
CN110869028B (zh) 2017-03-14 2023-01-20 吉利德科学公司 治疗猫冠状病毒感染的方法
CN115403626A (zh) 2017-05-01 2022-11-29 吉利德科学公司 新结晶形式
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
SG11202004403QA (en) 2017-12-07 2020-06-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2019200005A1 (en) 2018-04-10 2019-10-17 Atea Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis
WO2020157694A1 (en) * 2019-02-01 2020-08-06 Janssen Biopharma, Inc. Antiviral nucleosides and derivatives thereof
WO2021154687A1 (en) 2020-01-27 2021-08-05 Gilead Sciences, Inc. Methods for treating sars cov-2 infections
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN115298181A (zh) 2020-03-12 2022-11-04 吉利德科学公司 制备1’-氰基核苷的方法
EP4132651A1 (en) 2020-04-06 2023-02-15 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
CA3179226A1 (en) 2020-05-29 2021-12-02 Tomas Cihlar Remdesivir treatment methods
CN115996928A (zh) 2020-06-24 2023-04-21 吉利德科学公司 1’-氰基核苷类似物及其用途
PE20231983A1 (es) 2020-08-27 2023-12-12 Gilead Sciences Inc Compuestos y metodos para el tratamiento de infecciones virales
WO2023167944A1 (en) 2022-03-02 2023-09-07 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2083386C (en) 1990-06-13 1999-02-16 Arnold Glazier Phosphorous prodrugs
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6566365B1 (en) 1999-11-04 2003-05-20 Biochem Pharma Inc. Method for the treatment of Flaviviridea viral infection using nucleoside analogues
EA200200778A1 (ru) 2000-02-18 2003-06-26 Шайре Байокем Инк. СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИИ ГЕПАТИТА С В ОРГАНИЗМЕ ХОЗЯИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ПРОТИВ ФЛАВИВИРУСА, СОЕДИНЕНИЕ ФОРМУЛЫ Ib - АКТИВНЫЙ АГЕНТ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИИ ГЕПАТИТА С ИЛИ ФЛАВИВИРУСА (ВАРИАНТЫ)
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
KR101201552B1 (ko) 2000-10-18 2012-11-15 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
RS50236B (sr) * 2001-01-22 2009-07-15 Merck & Co.Inc., Nukleozidni derivati kao inhibitori rnk-zavisne rnk virusne polimeraze
US20040006002A1 (en) 2001-09-28 2004-01-08 Jean-Pierre Sommadossi Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
AT410792B (de) 2001-12-28 2003-07-25 Dsm Fine Chem Austria Gmbh Verfahren zur herstellung von geschützten, enantiomeren-angereicherten cyanhydrinen durch in-situ-derivatisierung
CN1849142A (zh) 2002-11-15 2006-10-18 埃迪尼克斯(开曼)有限公司 2′－支链核苷和黄病毒突变
AU2005285045B2 (en) 2004-09-14 2011-10-13 Gilead Pharmasset Llc Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
JP5089395B2 (ja) * 2004-10-29 2012-12-05 バイオクライスト ファーマシューティカルズ， インコーポレイテッド 治療用フロピリミジンおよびチエノピリミジン
WO2006121820A1 (en) 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en) 2005-05-16 2007-03-08 Valeant Research & Development 3', 5' - cyclic nucleoside analogues for treatment of hcv
WO2008079206A1 (en) 2006-12-20 2008-07-03 Merck & Co., Inc. Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection
US7951789B2 (en) 2006-12-28 2011-05-31 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of viral infections
JP2010515680A (ja) 2007-01-05 2010-05-13 メルク・シャープ・エンド・ドーム・コーポレイション Ｒｎａ依存性ｒｎａウイルス感染症の治療用としてのヌクレオシドアリールホスホロアミデート
US8440813B2 (en) 2007-01-12 2013-05-14 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs
WO2008141079A1 (en) 2007-05-10 2008-11-20 Biocryst Pharmaceuticals, Inc. Tetrahydrofuro [3 4-d] dioxolane compounds for use in the treatment of viral infections and cancer
WO2010036407A2 (en) * 2008-05-15 2010-04-01 Biocryst Pharmaceuticals, Inc. Antiviral nucleoside analogs

Also Published As

Publication number Publication date
DK2396340T3 (en) 2014-03-10
AU2015238785B2 (en) 2017-02-16
AU2017202413A1 (en) 2017-05-04
EP2396340B1 (en) 2013-12-18
HRP20140219T1 (hr) 2014-04-11
CN102348713B (zh) 2015-12-02
CN102348713A (zh) 2012-02-08
AU2010213873B2 (en) 2015-07-09
CO6420354A2 (es) 2012-04-16
AP2011005818A0 (en) 2011-08-31
UA110093C2 (uk) 2015-11-25
HK1163108A1 (en) 2012-09-07
SG173186A1 (en) 2011-09-29
WO2010093608A1 (en) 2010-08-19
NZ594370A (en) 2014-01-31
AU2010213873A1 (en) 2011-09-01
ES2453078T3 (es) 2014-04-03
EP2396340A1 (en) 2011-12-21
CA2751277A1 (en) 2010-08-19
PE20120257A1 (es) 2012-03-29
KR101834707B1 (ko) 2018-03-05
KR20170039759A (ko) 2017-04-11
SMT201400056B (it) 2014-07-07
IL214396A (en) 2014-07-31
KR20110116046A (ko) 2011-10-24
PT2719701T (pt) 2017-06-29
PT2396340E (pt) 2014-03-26
EP2719701B1 (en) 2017-04-05
IL214396A0 (en) 2011-09-27
JP2012517444A (ja) 2012-08-02
AP2922A (en) 2014-05-31
KR101724759B1 (ko) 2017-04-07
JP2014185183A (ja) 2014-10-02
MX345562B (es) 2017-02-03
ES2628842T3 (es) 2017-08-04
CA2751277C (en) 2018-10-30
CL2011001906A1 (es) 2012-03-30
US20100203015A1 (en) 2010-08-12
US8012942B2 (en) 2011-09-06
BRPI1013643A2 (pt) 2016-04-19
SI2396340T1 (sl) 2014-04-30
PE20161067A1 (es) 2016-10-23
UA112140C2 (uk) 2016-07-25
JP5746638B2 (ja) 2015-07-08
MX2011008409A (es) 2011-10-21
EP2719701A1 (en) 2014-04-16
PE20160858A1 (es) 2016-09-03
JP5951690B2 (ja) 2016-07-13
AU2017202413B2 (en) 2018-09-13
AU2015238785A1 (en) 2015-10-29
EA025085B1 (ru) 2016-11-30
EA201190110A1 (ru) 2012-02-28

Similar Documents

Publication Publication Date Title
AP2922A (en) Carbra-nucleoside analogs for antiviral treatment
HK1216750A1 (zh) ' - 用於抗病毒治療的 '替代咔核苷類似物
HK1253517B (zh) 抗病毒化合物
HRP20170197T1 (hr) 2' -fluoro supstituirani karba-nukleozidni analozi za antiviralno liječenje
HK1182387A1 (en) 1-substituted-carba-nucleoside prodrugs for antiviral treatment 1--carba-
IL216026A0 (en) Heterocyckic antiviral compounds
GB0914473D0 (en) Antiviral compounds
GB0906209D0 (en) Antiviral compounds
GB0908677D0 (en) Antiviral compounds